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In addition to its anti-coagulant effect, heparin inhibits 
the growth of several types of cells. Recent studies sug-
gest that heparin inhibition of proliferation of cul-
tured human keratinocytes results primarily from 
interaction with keratinocyte-generated, heparin-
binding autocrine growth factors. In this study, we 
evaluated whether non-anticoagulant heparin analogs, 
and oligosaccharide fragments of heparin, retain the 
growth-inhibitory properties of whole heparin on 
human keratinocytes. Second-passage neonatal kerati-
nocytes were grown in serum-free keratinocyte 
growth medium, and the effect of heparin analogs was 
studied in the absence of exogenous growth factors 
using keratinocyte-conditioned medium. Cell prolif-
eration was assessed by measurement of both DNA 
content and [3H]-thymidine incorporation. The addi-
tion of heparin inhibited the conditioned medium-sti-
mulated keratinocyte proliferation in a dose-depen-
dent manner, with 80% inhibition at or above 
10 J.lg/ ml. Moreover, heparin was not toxic to kerati-
nocytes (as detected by propidium-iodide fluorescence 
I n addition to its ant icoagulant effects, the sulfated glycosa-minoglycan heparin also possesses anti proliferative effects towards several different cell types, both ill Vil/O and in vitro [1 - 6) . The effects of heparin on cell proliferation are be-lieved to be, at least in part, mediated by its interaction with 
various growth factors such as acidic and basic fibroblast growth 
factor (FGF) [7 - 9), platelet-derived growth factor (PDGF) [to), 
heparin-binding epidermal growth factors [11), amphiregulin [12), 
and certain growth-factor receptors [13,14). Several recent studies 
suggest that human keratinocyte growth is also modulated by hepa-
rin and other sulfated glycosaminoglycans. Heparin inhibits the 
growth factor- independent proliferation of keratinocyte culnlres 
plated at high density [15). Moreover, the importance of cell-surface 
glycosaminoglycans on the regulation of keratinocyte growth and 
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and by retention of normal protein synthetic rate) and 
it did not induce terminal differentiation (as measured 
by cornified envelope formation). Furthermore, hepa-
rin stimulated protein secretion by keratinocytes with-
out altering rates of protein synthesis. The growth-in-
hibitory effects of heparin oligosaccharides were 
directly proportional to their chain length. The hexa-
saccharide unit represented the minimum require-
ment for inhibition, whereas decasaccharide units 
demonstrated nearly equivalent growth inhibition to 
native heparin. Finally, two non-anticoagulant hepa-
rin analogs were equipotent with heparin in inhibiting 
autocrine-induced keratinocyte growth. These studies 
show that the growth-inhibitory activities of heparin 
are independent of the anticoagulant effects and that 
decasaccarides contain the optimal oligosaccaride 
chain length for the antiproliferative effect in human 
keratinocytes. Key JVords: glycosaminoglycans/heparin sul-
fate / epidermis/skin/ groJVth factors / hyperproliferation. ] In-
vest Dermato1103:647 - 650, 1994 
differentiation is further supported by the observation that enzy-
matic deglycosylation and metabolic undersulfation of cell-surface 
proteoglycans of squamous cell carcinoma cells inhibit growth in 
culture [16). Furthermore, a keratinocyte-specific proteoglycan, 
epican, which is rich in heparan sulfate, is specifically expressed in 
the epidermis [17). Finally, the proteoglycans of differentiating 
keratinocytes contain higher levels of heparan sulfate than proteo-
glycans of proliferating keratinocytes [18), and heparan sulfate 
chain synthesis is upregulated during the terminal differentiation of 
cultured human keratinocytes [19)' 
Several dermatologic disorders, including psoriasis [20,21), are 
characterized by prominent epidermal hyperplasia. As early as 1953, 
it was reported that heparin therapy might be beneficial to psoriatic 
patients unresponsive to other forms of therapy [22). More recently, 
systemic heparin therapy was shown to be beneficial for the treat-
ment of severe generalized psoriasis [23). However, the efficacy of 
systemic heparin therapy in the treatment of psoriasis has been 
questioned [24), and further, the potential utility of native heparin is 
limited potentially by its primary anticoagulant properties. Thus, 
identification of heparin analogues or active fragments of heparin 
that retain its growth inhibitory, but not its anticoagulant, proper-
ties would be of interest. Recently, heparin-derived hexa- to deca-
saccharides have been described that retain the growth-modulating 
activities of whole heparin [25,26). In the present study, we com-
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pared the effects of native heparin, heparin that lacks anticoagulant 
activity, and heparin fragments of differing polysaccharide lengths 
on the growth and differentiation of normal human neonatal kera-
tinocytes in culture. Our data demonstrate that heparin not only 
inhibits keratinocyte growth, but that it does so without inducing 
terminal differentiation in culture. Furthermore, non-anticoagulant 
heparin, as well as dec a- and octasaccharides derived from native 
heparin, are as effective as native heparin in the inhibition of 
growth-factor - independent keratinocyte proliferation ill vitro. 
MATERIALS AND METHODS 
Materials MCDB lS3 (keratinocyte basal medium [KBM]) and complete 
keratinocyte growth medium (KGM) were purchased from Clonetics Cor-
poration, San Diego, CA. KGM contained the fo llowing growth factors 
added to the KBM: epidermal growth factor (10 ng/ml), insulin (Sl1g/m1), 
hydrocortisone (SI1M), phosphatidylethanolamine (0.1 mM), ethanol-
amine (0.2 mM), bovine pituitary extract (70l1g protein/ml), penicillin/ 
streptomycin (100I1g/ml), and fungizone (2.S mg/ml). Whole heparin 
from porcine intestinal mucosa was purchased from Sigma Chemical Com-
pany (St. Louis, MO). The heparin oligosaccharides and non-anticoagulant 
heparins (NAC-heparin-l, NAC-heparin-2) were kindly provided by Dr. 
Robert). Stack (Glycomed Inc., Alameda, CAl. Homogeneously sized hep-
arin oligosaccharides were prepared from heparin following partial depoly-
merization with nitrous ac id, reduction with sodium borohydride, and frac-
tionation by gel permeation chromatography [2S]. Non-anticoagulant 
heparins were prepared from whole heparin by deacetylation with hydrazine 
followed by periodate oxidation and borohydride reduction. Typical 
weight-average molecular weights for whole heparin and NAC heparin-l 
and -2 were 12,SOO, 7,000, and 10,SOO, respectively (as measured by analyti-
cal size exclusion high-performance liquid chromatography [HPLC]). Both 
N AC-heparin analogues retained -10% of heparin anticoagulant activity (as 
measured by aPTT). [3H)-L-thymidine (sp act 42 Ci/mmol) was purchased 
from Amersham (Arlington, 11). 
Cell Culture Second-passage keratinocytes isolated from neonatal 
human fo reskins were grown in serum-free KGM, as described previously 
[27] . Briefly, keratlnocytes were isolated from newborn human foreskins 
using 0.2S% trypsin. Primary cultures were grown to 60 - 70% confluence 
in KGM containing 0.07 mM calcium before switching to KBM containing 
0.07 mM calcium or to different conditions, as described. Conditioned me-
dium was collected after incubation of keratinocytes (80-90% confluent) 
with KBM for different times (up to 24 h), and was used immediately or 
stored at -4°C until usc. Keratinocytes were used at approximately 70% 
confluence for studies with heparin or heparin analogues, which were added 
simultaneously with conditioned medium unless otherwise noted. All ex-
periments were performed a minimum of three times, with representative 
data presented. Statistical analysis was performed using the Student t test, 
where appropriate. 
Growth and Differentiation Markers Cellular DNA was assayed by 
the method of Labarca and Paigan using the fluorescent reagent bis benzimi-
dazole [28). [3H]-thymidine incorporation into cellular DNA was quanti-
tated by incubating cells with [3H]-thymidine (lI1Ci/ml medium) in the 
presence of 0.1 mM cold thymidine for 2 hat 37"C. The amount of tritium 
associated with trichloroacetic acid (TCA)-precipitable macromolecules 
then was determined by liquid scintillation spectroscopy. 
Cornified envelope (CE) formation, a marker for the terminal differentia-
tion of keratinocytes, was determined by the method of !{jng el al [29]. 
Briefly. the cornified envelope precursor proteins were labeled with [3SS]_L_ 
methionine by incubating cultures with [3SS)-methionine (2jlCijmJ me-
dium) for 48 h prior to harvest. The rate of CE formation in the 48-h period 
was then determined by dissolving the cells in 2% sodium dodecyl sulfate 
(SDS)/20 mM dithiothreitol (DTT) with boiling for 10 min, and radioac-
tiviry present in the insoluble material was quantitated by liquid scinti llation 
spectroscopy. The amount of [3SS]-mcthionine incorporated into total cell u-
lar proteins was determined by quantitating the radioactivity in an aliquot of 
the total cel l homogenate precipitated with 10% TCA. 
RESULTS 
Heparin and its Non-Anticoagulant Analogues Inhibit 
Conditioned-Medium - Stimulated Ketatinocyte Growth 
Previous studies by Cook et al have demonstrated that heparin and 
the related sulfated glycosaminoglycan, heparan sulfate, inhibit 
conditioned-medium - stimulated keratinocyte growth [12]. In this 
study, we evaluated the effects of non-anticoagulant heparin ana-
logues (NAC-heparin) on conditioned-medium - stimulated kerati-
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Figure 1. Concentration dependence of conditioned-medium-
stimulated growth inhibition by heparin and NAC-heparins. Human 
keratinocytes were grown in serum-free KGM to 90% confluence and 
switched to KBM. Twenty-four hours later (= 24-h conditioned KBM), 
indicated amounts of heparin or N AC-hcparins were added to the cells in the 
KBM medium. After an additional 24-h incubation, DNA synthesis rates of 
the cultures were determined by a 2-h [3H]-thymidine incorporation assay. 
Heparin and both NAC-heparin analogues inhibited the conditioned-
medium-stimulated growth in a dose-dependent manner with equivalent 
potency. Data represent mean of triplicate determinations for control (con-
ditioned medium control = 100%) and for each concentration of heparin 
and NAC-heparin. Error bars omitted for clarity, with SD < S% for each 
determination. Similar results were observed in three separate experiments. 
nocyte growth in culture and compared their potency to that of 
native heparin. Exposure of keratinocytes to 24-h conditioned me-
dium (i.e., CM = KBM exposed to 90% confluent cultured human 
keratinocytes for 24 h stimulated [3H]-thymidine incorporation 
four- to fivefold over keratinocytes exposed to KBM alone (data not 
shown). The simultaneous addition of heparin with 24-h-
conditioned KBM significantly inhibited keratinocyte proliferation 
(Fig 1). This inhibitory effect of native heparin was concentration 
dependent, maximal inhibition occurring at or above 10 J1g/ml. 
Two NAC-heparin analogues displayed similar potency and dose 
dependency as native heparin (Fig 1). When h eparin was added 
along with fresh KBM, the growth-inhibitory effect was apparent 
after 8 h of heparin exposure (data not shown), consistent with the 
time required to generate autocrine factors [15] . Long-term incuba-
tion with heparin (2 and 4 d; 10 J1g/ml) decreased DNA content by 
44 and 67% versus control, respectively. Heparin did not appear to 
be directly toxic to keratinocytes, as removal of heparin from the 
growth medium resulted in the reversal of growth inhibition of 
keratinocytes, i.e., within 12 h after heparin removal the rate of 
DNA synthesis achieved levels comparable to untreated control 
cultures (data not shown). Moreover, incubation of keratinocytes 
with 50 J1g/ml heparin did not alter permeability of the cultured 
cells, as measured both by trypan blue and propidium iodide-exclu-
sion studies [30] (data not shown). These studies demonstrate that 
heparin and two non-anticoagulant heparin analogues inhibit the 
autocrine-factor- induced growth of keratinocytes in a non-toxic, 
dose-dependent, and reversible manner. 
Heparin and Heparin Analogues Inhibit Keratinocyte 
Growth Without Inducing Formation of Cornified Enve-
lopes Many of the regulators of keratinocyte growth in culture, 
such as tumor necrosis factor (TNF)a, 1 ,25-dihydroxy vitamin 03, 
and increasing extracellular calcium concentration, inhibit growth 
and also induce terminal differentiation. However, some agents, 
such as transforming growth factor (TGF)-,B, appear to inhibit ke-
ratinocyte growth without affecting terminal differentiation [31] . 
To determine whether heparin-mediated growth inhibition is ac-
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Figure 2. Effect of heparin on protein secretion by cultured kerati-
nocytes. Human keratinocytes grown in KGM/0.07 mM calcium were 
exposed [0 different concentrations of heparin for 48 h. Cells were labeled 
with [35SJ-methionine (5 jlCijwell) during the 48 h of heparin treatment. 
After the treatment, medium was collected and cells were dissolved in 2% 
505/20 mM dithiothreitol. The amount of newly synthesized [35S]- labeled 
proteins secreted into the medium was quantitated after 10% TCA precipi-
tation of an aliquot of the medium. Data represent mean of triplicate deter-
minations (± SO). Approximately 1 % of total labeled cellu lar protein was 
secreted into the medium by control cells. 
companied by an induction of late-stage events in keratinocyte dif-
ferentiation, we next determined the effects of heparin on cornified 
envelope formation. Incubation with heparin (10 ,ug/ml) for 48 h 
neither stimulated nor inhibited cornified envelope formation in 
keratinocytes and did not alter the rate of protein synthesis by kera-
tinocytes (data not shown) . However, at heparin concentrations of 
0.3 ,ug/ml and higher, heparin increased the re lease of[35S] -metlu-
onine-labeled proteins into the medium (Fig 2) (p < 0.01). These 
results suggest that heparin inhibition of conditioned-medjum-
stimulated keratinocyte growth is not accompanied by the induc-
tion of terminal events in keratinocyte terminal differentiation but 
may stimulate secretion of newly synthesized proteins . 
Growth Inhibition of Keratinocytes by Oligosaccharide 
Fragments of Native Heparin Previous studies in other cell 
types have shown that the anti proliferative effects of heparin are 
size dependent [26]. We next compared five heparin fra~ments of 
varying saccharide chain lengths (from 2 to 10 saccharIde UJ1lts) 
with native commercial heparin (porcine intestinal mucosa) for 
their effect on conditioned-medium-stimulated growth of cul-
tured human keratinocytes. At low concentrations (1 pg/ml and 
lower), inhibition of thymidine incorporation required heparin oli-
gosaccharide chains containing eight or more saccharide units, 
whereas hexasaccharide units were only minimal inhibitory (Fig 
3). At higher concentrations (20 ,ug/ml), tetrasaccharide and disac-
charide units were not inhibitory (data not shown), whereas the 
decasaccarides were nearly equipotent with native heparin (c.f. Fig 
1). Moreover, the growth-inhibitory activity of the oligos was di-
rectly proportional to the size of the molecule, i.e ., the larger the 
o ligosaccharide chain, the greater its growth-inhibitory effects (Fig 
3) at a given concentration. These data demonstrate that keratino-
cyte growth is inhibited by heparin fragments containing eight or 
more saccharides and suggest that keratinocytes may require larger 
fragments of heparin than some other cells to inhibit growth. 
DISCUSSION 
The glycosaminoglycans heparan sulfate and its close relative hepa-
rin display growth-modulatory activities in a number of different 
types of cells [1-6]. In the present study, we have demonstrated that 
heparin and its non-anticoagulant analogues markedly inhibit the 
autocrine growth-factor- induced proliferation of subconfluent 
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cultured human keratinocytes, similar to that described previously 
for heparin and heparan sulfate [15]. Whereas the sensitivity of 
keratinocytes to heparin-induced growth inhibition and the time-
course of inhibition also appear to be similar to those of other cell 
types, sensitivity to the size of heparin saccharide chains appears to 
differ in keratinocytes. Hexasaccharides of heparin were only mjni-
mally inhibitory to keratinocyte growth even at high concentra-
tions (20 ,ug/ml), whereas octasaccharides or higher chain lengths 
were required for comparable growth inhibition with heparin. In 
comparison, a synthetic penta saccharide of heparin was antiprolif-
erative for rat and calf aortic smooth muscle cells, whereas hexasac-
charide fragments of heparin were required to inhibit the growth of 
rat cervical epithelial cells [26]. Furthermore, adrenocortical endo-
thelial cells appear to require 10 oligosaccharide residues to support 
the mitogenjc activity of basic FGF [25], whereas eight oligosaccha-
ride residues were sufficient for inhibiting basic FGF activity in 
lymphoid BaF3 cells [32] . 
Although our findings suggest a possible role for heparin/he-
paran sulfate glycosaminoglycans in the regulation of keratinocyte 
growth, heparin did not subsequently induce the terminal events in 
keratinocyte differentiation in culture, i.e., it did not induce forma-
tion of CEs. However, prior studies have shown that differentiated 
keratinocyte cultures produce high levels of heparan-sulfate-
containing proteoglycans and increased levels of heparan-sulfate-
free chajns [17,19]. The observation that increased synthesis of the 
heparan-sulfate - free chain occurs in stratified cultures [19], to-
gether with the inhibitory effects of exogenous heparin reported 
here, indicate a role for these molecules in the regulation of kerati-
nocyte growth, possibly through a mechanism involving binding 
and inactivation of autocrine growth factors. Because keratinocytes 
in culture produce and secrete various growth factors, including 
TGF-Q, TGF-p, PDGF, heparin-binding epidermal growth factors 
(EGFs), and amphiregulin (keratinocyte autocrine factor) 
[12,15,33]' the growth-inhibitory effects of heparin and its ana-
logues could be explained in part by the binding of heparin to 
certain growth factors, rendering them unavailable to cell-surface 
receptors. Indeed, the similarity of the time courses of both auto-
crine growth stimulation and the heparin inhibition of autocrine-
stimulated growth are consistent with such a mechanism. More-
over, the cell-surface proteoglycan syndecan-l binds to growth 
factors and is required for growth-factor-mediated signal transduc-
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Figurc 3. Concentration dcpcndence of heparin oligosaccharidc in-
hibition of conditioned-medium-stimulated kcratinocyte growth. 
Human kcratinocytes were exposed for 48 h to ICBM in the absence 
(control = 100%) or in the presence of heparin oligosaccharides (from 0.01 
to 10 ,ug/ml), with sizes varying from [wo to ten saccharide units. Similar 
results were obtained in three separate experiments. Data are expressed as 
percent of non - heparin-treated control DNA synthesis (PH]-thymidine 
incorporation), and represent the mean for triplicate determinations. Error 
bars omitted for clarity (SO < 5% for each value). 
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tion events in all cells, including keratinocytes [18]. Levels of syn-
decan-1 also increase in stratified keratinocytes, although the size 
and total content of heparin sulfate in syndecan-1 is higher in undif-
ferentiated monolayers of keratinocyte cultures [19]. Together, 
these studies suggest that proteoglycans containing heparin sulfate 
and free heparin sulfate play a unique role in the regulation of 
growth and/or differentiation of epidermal keratinocytes. 
Alternatively, the increased levels of proteins released by hepa-
rin-treated keratinocytes suggests the possibility that heparin may 
induce the synthesis or secretion of factor(s) that in turn could 
mediate keratinocyte growth. For example, in smooth muscle cells, 
heparin increases the secretion of two non-collagenous proteins of 
molecular weight 35 and 37 kd without affecting total protein syn-
thesis rate by these cells [34] . Furthermore, TGF-p appears to be a 
prime candidate for a heparin-induced growth-inhibitory factor in 
keratinocytes, as TGF-p is secreted by keratinocytes [35] and, like 
heparin, inhibits the growth of keratinocytes without affecting 
their differentiation [31]. Cook et al [15] have demonstrated that 
keratinocyte-conditioned medium (in concentrations above 1X) in-
hibits rather than enhances keratinocyte growth, further supporting 
the notion that keratinocyte-conditioned medium may also contain 
an inhibitory factor, possibly active TGF-p. Thus, heparin in the 
medium may participate in the release or activation of the latent 
form of TGF-p or other proteins from their binding sites in the 
extracellular matrix of keratinocytes. 
In summary, our study demonstrates that heparin and two non-
anticoagulant analogues inhibit keratinocyte growth similar to that 
of other cell types such as vascular smooth muscle cells and cervical 
epithelial cells. Furthermore, heparin fragments above eight sac-
charide units were equally effective toward inhibiting autocrine-in-
duced keratinocyte growth. The finding that heparin analogues 
inhibit keratinocyte proliferation will allow further delineation of 
the role of these glycosaminoglycans in epidermal biology. 
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